Saturday, June 3, 2006

OncoLink coverage of the Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, in Atlanta, GA OncoLink reporters provide in-depth, up-to-the-minute coverage of sessions and presentations.

A Phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Presenter: Roy S. HerbstPresenter's Affiliation: M. D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Death receptors, such as TNF-alpha receptor, Fas, and TRAIL-R (TNF-alpha Related Apoptosis Inducing Ligand...
Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 Presenter: C. Pepe Presenter's Affiliation: Princess Margaret Hospital, Toronto, Canada Type of Session: Scientific Background There is a high incidence of lung cancer in the elderly. The elderly are under-represented in clinical trials....
Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Presenter: G.M. Strauss Presenter's Affiliation: CALGB Type of Session: Scientific Background Lung cancer is the number one cause of cancer death in America. A meta-analysis published in 1995 demonstrated a marginally significant...
Dactinomycin (A) and vincristine (V) with or without cyclophosphamide (C) and radiation therapy (RT) for newly diagnosed patients with low-risk embryonal/botryoid rhabdomyosarcoma (RMS). An IRS-V report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (STS COG) Presenter: Walterhouse JL et al.Presenter's Affiliation: Children's Hospital of Los Angeles, Los Angeles, CAType of Session: ScientificBackground The IRS-III and –IV studies defined 3 risk groups of rhabdomyosarcoma patients: low-risk...
HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors Presenter: A. PatanaikPresenter's Affiliation: Cancer Therapy and Research Center, San Antonio, TXType of Session: ScientificBackground Death receptors, such as TNF-alpha receptor, Fas, and TRAIL-R (TNF-alpha Related Apoptosis Inducing Ligand...
Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. Presenter: J.P. PignonPresenter's Affiliation: Institut Gustave-Roussy, Villejuif, FranceType of Session: ScientificBackground Lung cancer is the number one cause of cancer death in America. A meta-analysis published in 1995 demonstrated...
Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. Presenter: Minesh P. MehtaPresenter's Affiliation: University of Wisconsin, Madison, WIType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. It can...
Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS) Presenter: Breslow EJ et al.Presenter's Affiliation: Children's National Medical Center, Washington D.C.Type of Session: ScientificBackground CCSK originally described in early 1970s and characterized by tendency to metastasize to bone as well...
Site of metastases does not influence the clinical outcome of children with metastatic Germ Cell Tumors (GCT). A report from the Children's Oncology Group (COG) Presenter: Malogolowkin MH et al.Presenter's Affiliation: Children's Oncology Group, Arcadia, CAType of Session: ScientificBackground A previous protocol had randomized patients with either extragonadal GCT or high-risk gonadal GCT to high-dose...